Report Highlights
The global stem cell market reached over $5.9 billion in 2015 and will grow from about $6.7 billion in 2016 to nearly $12.3 billion in 2021, registering a compound annual growth rate (CAGR) of 13.1% from 2016 through 2021.
Report Includes
- An overview of the global market for stem cells and related technologies
- Analyses of global market trends, with data from 2014, 2015, estimates for 2016 and projections of compound annual growth rates (CAGRs) through 2021
- Information on the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market
- A look at the regulatory environment, healthcare policies, demographics, and other factors directly affecting stem cell-related markets
- Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities
- Examination of strategies employed by companies specializing in this field to meet the challenges of a competitive and fast-growing market
- Profiles of major players in the industry
Report Scope
This report discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting stem cells are reviewed, and the nature and structure of the stem cell industry is discussed with profiles of the leading companies, including recent M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.
Analyst Credentials
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the stem cell marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.
Report Highlights
BCC Research projects that the global stem cell market will grow from about $5.6 billion in 2013 to nearly $10.6 billion in 2018, registering a compound annual growth rate (CAGR) of 13.6% from 2013 through 2018.
Report Includes
- An overview of the global market for stem cells and related technologies.
- Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2018.
- Information on the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market.
- Examination of strategies employed by companies specializing in this field to meet the challenges of a competitive and fast-growing market.
- Comprehensive profiles of major players in the field.
Report Highlights
The global market for stem cell products was $3.8 billion in 2011. This market is expected to reach nearly $4.3 billion in 2012 and $6.6 billion by 2016, increasing at a compound annual growth rate (CAGR) of 11.7% from 2011 to 2016.
Report Highlights
This Report:
- The U.S. market for stem cells in regenerative medicine is expected to increase from $112.0 million in 2007 to an estimated $423.1 million by the end of 2012, a compound annual growth rate (CAGR) of 30.5%.
- Stem cell banking was valued at $58.9 million in 2005 and $65.9 million in 2007. This is expected to rise to $155.7 million in 2012, for a CAGR of 18.8%.
- Human adult stem cells for cell-based therapeutics were worth $21.4 million in 2006. This increased to $28.1 in 2007 and should increase to $173.8 in 2012 at a CAGR of 44.0%.
Report Highlights
-
The worldwide market for stem cell, cytokine and growth factor therapies is estimated at $12.7 billion in 2005 and, rising at an average annual growth rate (AAGR) of 10.3%, is expected to reach $20.7 billion in 2010.
-
Nearly 98% of the market is consumed by blood and immune system treatments, a figure that will shrink slightly to 95% in 2010.
-
Revenues worldwide for stem cell, cytokine and growth factor therapies for all other bodily systems are expected to rise at an AAGR of 26.4% to just over $1 billion in 2010.
-
The first off-the-shelf cell therapy approved by the FDA was for wound treatment. Recently, a bone morphogenic protein (BMP) has been approved for the acceleration of spinal fusions.
Report Highlights
-
Hematopoietic stem cell therapies are still the most widely used and generate the most revenue, as can be seen in the table below. We project this will remain the case through 2007, by which time over $1.3 billion in revenues will be generated by the purchase of products and services in support of these therapies. The average annual growth rate for these products, from 2001 to 2007 is expected to be 29.2%. These revenue projections, like all others in this report, exclude fees charged by physicians for their services and general hospital costs.
-
Skin, bone, and cartilage are largely derived from mesenchymal stem cells, as are tendons, ligaments, and fat cells (the epidermal layer of skin, however, comes from the ectoderm). Skin replacement to treat ulcers, burns, and surgical wounds was the first "off-the-shelf" living cell therapy to be approved. The progenitor cells for these products are fibroblasts and keratinocytes from newborn human foreskin. Chondrocytes (cartilage producing cells) are used to repair articular cartilage after knee injuries, with additional applications on the way. Combined cell and tissue engineering approaches for repairing bone fractures are being developed. In 2001, we estimate that progenitor cell therapies to replace skin, bone, or cartilage will generate about $43 million in revenues. By 2007, we expect this category to grow ten-fold to $457 million, as indicated above, for an AAGR of 48.1%.
Related Reports
Global Markets for Diabetes Therapeutics and Diagnostics
The global market for diabetes therapeutics and diagnostics is estimated to increase from $102.2 billion in 2023 to reach $132.0 billion by 2028, at a compound annual growth rate (CAGR) of 5.2% from 2023 through 2028.
Global Market for Stem Cells
The global stem cell market reached $32.1 billion in 2022 and should reach $65.6 billion by 2027, with a compound annual growth rate (CAGR) of 15.3% during the forecast period of 2022-2027.
Cancer Stem Cells: Technologies and Global Markets
The global market for cancer stem cells should grow from $2.1 billion in 2021 to $4.4 billion by 2026, at compound annual growth rate (CAGR) of 16.1% for the period of 2021-2026.
Biomarkers: Technologies and Global Markets
The global market for biomarkers should grow from $43.3 billion in 2020 to $92.1 billion by 2025, at compound annual growth rate (CAGR) of 16.3% for the period of 2020-2025.
Recent Reports
Bioprocess Optimization and Digital Bio-manufacturing: Global Markets
The global market for bioprocess optimization and digital biomanufacturing is expected to grow from $24.3 billion in 2024 and is projected to reach $39.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2024 to 2029.
Global DNA Sequencing: Research, Applied and Clinical Markets
The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.
Artificial Intelligence (AI) in Cancer
The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More